Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jan 11, 2007

Cepheid and Idaho Settle 2005 PCR-Related Lawsuit

  • Cepheid and Idaho Technology have agreed to resolve a dispute related to their intellectual property, through a settlement and cross-license agreement.

    The agreement will lead to the dismissal of a lawsuit initiated by Idaho Technology and its licensor, University of Utah Research Foundation, in 2005. The dispute claimed infringement of three patents related to rapid PCR methods and instrumentation, the use of SYBR® Green I in PCR reactions, and certain methods of analysis of real-time PCR data.

    As part of the settlement Cepheid will make a one-time payment to Idaho of $3.35 million. Each firm will have paid-up licenses under certain of the other's patents to continue to make and sell their respective lines of products.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »